Literature DB >> 8227409

Expression of MUC2 epithelial mucin in breast carcinoma.

M D Walsh1, M A McGuckin, P L Devine, B G Hohn, R G Wright.   

Abstract

AIMS: To examine the expression of the MUC2 epithelial mucin in breast carcinoma; to relate this to patient survival.
METHODS: Sections from 210 breast carcinomas were stained with the anti-MUC2 core protein monoclonal antibody, 4F1, using an immunoperoxidase technique. The proportion of tumour cells positively stained and the localisation and intensity of any staining were recorded. Expression of MUC2 was compared with histological type and grade, tumour size, presence of nodal metastases, presence of oestrogen receptors, and menopausal status. The prognostic value of MUC2 expression was examined using Kaplan-Meier survival analysis.
RESULTS: MUC2 mucin was detected in 19% of cases of invasive carcinoma, in 11% of cases of carcinoma in situ, where present, but very rarely in adjacent normal breast epithelium. Presence of MUC2 was significantly associated with a shorter disease free interval (p < 0.05), although the observed difference in duration of overall survival was not significant.
CONCLUSIONS: The MUC2 detected in breast carcinoma may be underglycosylated or staining may represent detection of the protein core before the completion of glycosylation. The virtual absence of 4F1 reactivity in normal breast epithelium suggests that, unlike the MUC1 mucin, the MUC2 mucin is not highly expressed by these cells. The mechanism by which expression of MUC2 affects the biology of breast tumours is unclear, although expression may be a reflection of general derepression of genes during tumour progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227409      PMCID: PMC501619          DOI: 10.1136/jcp.46.10.922

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  16 in total

1.  Prognostic factors in breast cancer: immunohistochemical staining for SP1 and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status.

Authors:  C Wright; B Angus; J Napier; M Wetherall; Y Udagawa; J R Sainsbury; S Johnston; F Carpenter; C H Horne
Journal:  J Pathol       Date:  1987-12       Impact factor: 7.996

Review 2.  Pathology and breast screening.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1990-02       Impact factor: 5.087

3.  Molecular cloning of human intestinal mucin cDNAs. Sequence analysis and evidence for genetic polymorphism.

Authors:  J R Gum; J C Byrd; J W Hicks; N W Toribara; D T Lamport; Y S Kim
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

4.  Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11.

Authors:  B Angus; J Napier; J Purvis; I O Ellis; R A Hawkins; F Carpenter; C H Horne
Journal:  J Pathol       Date:  1986-08       Impact factor: 7.996

5.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.

Authors:  S J Gendler; C A Lancaster; J Taylor-Papadimitriou; T Duhig; N Peat; J Burchell; L Pemberton; E N Lalani; D Wilson
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

6.  The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas.

Authors:  M J Wilkinson; A Howell; M Harris; J Taylor-Papadimitriou; R Swindell; R A Sellwood
Journal:  Int J Cancer       Date:  1984-03-15       Impact factor: 7.396

Review 7.  Mucins: structure, function, and associations with malignancy.

Authors:  P L Devine; I F McKenzie
Journal:  Bioessays       Date:  1992-09       Impact factor: 4.345

8.  Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.

Authors:  I O Ellis; C P Hinton; J MacNay; C W Elston; A Robins; A A Owainati; R W Blamey; R W Baldwin; B Ferry
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

9.  Assessment of milk fat globule membrane antibodies and lectins as markers of short-term prognosis in breast cancer.

Authors:  R A Walker
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

10.  Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.

Authors:  I O Ellis; J Bell; J M Todd; M Williams; C Dowle; A R Robins; C W Elston; R W Blamey; R W Baldwin
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  10 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

2.  Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.

Authors:  Anna Astashchanka; Thomas M Shroka; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2018-10-13       Impact factor: 4.872

3.  Cloning and characterization of the 5' flanking region of the sialomucin complex/rat Muc4 gene: promoter activity in cultured cells.

Authors:  S A Price-Schiavi; A Perez; R Barco; K L Carraway
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

4.  Immunohistochemical Study of MUC1, MUC2 and MUC5AC Expression in Primary Breast Carcinoma.

Authors:  Daxesh Shivabhai Patel; Siddhi Gaurish Sinai Khandeparkar; Avinash R Joshi; Maithili Mandar Kulkarni; Bhagyashree Dhande; Pranoti Lengare; Lokesh Ashok Phegade; Ketan Narkhede
Journal:  J Clin Diagn Res       Date:  2017-04-01

5.  Human mucin gene MUC4: organization of its 5'-region and polymorphism of its central tandem repeat array.

Authors:  S Nollet; N Moniaux; J Maury; D Petitprez; P Degand; A Laine; N Porchet; J P Aubert
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

6.  Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.

Authors:  Michael D Walsh; Margaret C Cummings; Sally-Ann Pearson; Mark Clendenning; Rhiannon J Walters; Belinda Nagler; John L Hopper; Mark A Jenkins; Graeme K Suthers; Jack Goldblatt; Kathy Tucker; Michael R Gattas; Julie L Arnold; Susan Parry; Finlay A Macrae; Michael A McGuckin; Joanne P Young; Daniel D Buchanan
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

7.  MUC5B leads to aggressive behavior of breast cancer MCF7 cells.

Authors:  Hélène Valque; Valérie Gouyer; Frédéric Gottrand; Jean-Luc Desseyn
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

8.  Identification of Potential Glycoprotein Biomarkers in Estrogen Receptor Positive (ER+) and Negative (ER-) Human Breast Cancer Tissues by LC-LTQ/FT-ICR Mass Spectrometry.

Authors:  Suzan M Semaan; Xu Wang; Alan G Marshall; Qing-Xiang Amy Sang
Journal:  J Cancer       Date:  2012-06-21       Impact factor: 4.207

9.  GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.

Authors:  Fahimeh Afzaljavan; Ayeh Sadat Sadr; Sevtap Savas; Alireza Pasdar
Journal:  Sci Rep       Date:  2021-01-18       Impact factor: 4.379

10.  Clinical Significance of Serum Membrane-Bound Mucin-2 Levels in Breast Cancer.

Authors:  Suleyman Bademler; Alisan Zirtiloglu; Murat Sari; Muhammed Zubeyr Ucuncu; Elif Bilgin Dogru; Senem Karabulut
Journal:  Biomolecules       Date:  2019-01-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.